Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Breast 1

Conditions

Breast Neoplasms 3Sarcoma 1Lymphoma 1Hematologic Neoplasms 1

Interventions

trametinib 2pertuzumab 2palbociclib 2dabrafenib 2copanlisib 2Sunitinib 2Specimen Handling 2Sorafenib 2Oxaliplatin 2Nivolumab 2Leucovorin 2Immunoglobulin G 2HhAntag691 2Fluorouracil 2Disulfides 2Dasatinib 2Bevacizumab 2Afatinib 2Ado-Trastuzumab Emtansine 22C4 antibody 2venetoclax 1ulixertinib 1trastuzumab biosimilar HLX02 1temsirolimus 1sapanisertib 1ruxolitinib 1romidepsin 1ribociclib 1relatlimab 1regorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Pravastatin × Breast × Clear all
NCT04190433 2023-05-24

Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial

Mayo Clinic

Phase 2 Withdrawn
BreastLymphoidOther hematologic neoplasmSarcoma

Breast Neoplasms, Lymphoma, Sarcoma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡